Abbisko Therapeutics has received US market approval for Pimjetmi (pimicotinib), its oral CSF-1R inhibitor, for adult patients with symptomatic tenosynovial giant cell tumour (TGCT) where surgical resection may cause worsening functional limitation or severe complications. It is the fourth marketing authorisation for the molecule after China, Canada and Switzerland, and the first Abbisko-discovered asset to reach US patients, with the US, Canadian and Swiss filings reviewed through Project Orbis.
The approval rests on the Phase III MANEUVER study, where pimicotinib achieved an objective response rate of 56% versus 3% for placebo at week 25 by blinded independent review, with statistically significant and clinically meaningful improvements in range of motion, physical function and pain, and long-term follow-up showing 77% of week-25 responders maintaining benefit a further 12 months later.
Under the 2023 licence with Merck KGaA worth up to USD 605.5 million, Abbisko has already received USD 13.52 million in milestone and first-quarter royalty payments and will collect USD 20 million on first US commercial sale, plus double-digit royalties on global net sales, validating a China-originated discovery-to-global-commercialisation model.

Email us at pmc@pharmcube.com for a free database trial, exclusive reports, or a 1-on-1 consultation